

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED  
JUN 04 2002

TECH CENTER 1800/12900

Approved for use through 10/31/2002. OMB 065-0003/2900  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/037,555
		Filing Date	01/03/2002
		First Named Inventor	Norbert HAUER
		Group Art Unit	1626
		Examiner Name	R. Ramsuer
		Attorney Docket Number	5/1265-1-D1
Sheet	2	of	3

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
[Signature]		Database WPI Sec. Ch. Week 199416, Derwent Pub. Ltd., London, GB; Class B05, AN 1994-128759; XP002186009	
		Database WPI Sec. Ch. Week 198537, Derwent Publ. Ltd., London, GB; Class B05, AN 1985-226638; XP002186010	
		Database WPI Sec. Ch. Week 198528, Derwent Pub. Ltd., London, GB; Class B03, AN 1985-168505; XP 002186011	
		YASHIRO, ET AL; "Tranilast (N-(3,4-dimethoxycinnamoyl) Anthranilic Acid) Down-Regulates the Growth of Scirrhou Gastric Cancer"; Anticancer Res., Bd. 17, Nr. 2A, 1997, 895-900	
		RALPH, ET AL; "Inhibitors of lipoxxygenase have antiproliferative effects on P815 murine mastocytoma cells"; Cancer Lett. (Shannon, Irel.) 1990, 49(3), 181-5	
		NIE, ET AL; "Inhibition of proliferation of MCF-7 breast cancer cells by a blocker of Ca2+-permeable channel"; Cell Calcium, Bd. 22, Nr. 2, 1997, 75-82	
		LIU, Y. ET AL; "Synthesis and antiinflammatory activity of (E)-4-cinnamoyloxy styrene derivatives", Zhongguo Yaowu Huaxue Zazhi (Chinese Journal of Medicinal Chemistry), Bd 9, Nr. 3, 1999, 186-191	✓
		NISHIZAWA, Y. ET AL; "Effects of antiallergic drugs on the proliferation of estrogen-sensitive mouse Leydig cell line"; Anticancer Res., Bd 19, Nr. 3A, 1996, 1241-1245	
		MURAHASHI, K. ET AL; "The combination therapy of scirrhou gastric carcinoma with tranilast and cisplatin"; Proc. of the Am. Assn. for Cancer Res. Annual, Bd 39, 1998, 308	
		BECKMAN, ET AL; "Phospholipid peroxidation in tumor promoter-exposed mouse skin", Carcinogenesis, Bd 15, Nr. 12, 1994, 2937-2944	
		MURAHASHI K. ET AL; "Tranilast, a fibroblasts inhibitor, inhibits the metastasis of gastric cancer cells", Proc. of the Am. Assn. for Cancer Res. Annual, Bd 40, 1999, 704	

Examiner Signature	[Signature]	Date Considered	2-10-03
--------------------	-------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B/PTO

(use as many sheets as necessary)

Sheet	3	of	3
-------	---	----	---

Application Number	10/037,555
--------------------	------------

<b>Filing Date</b>	01/03/2002
--------------------	------------

<b>First Named Inventor</b>	Norbert HAUEL
-----------------------------	---------------

Group Art Unit	1626
----------------	------

Examiner Name	R. Ramsuer
---------------	------------

Attorney Docket Number 5/1265-1-D1

Examin  
Initials\*Cite  
No. <sup>1</sup>

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

 $\tau^2$ 

BIOORGANIC &amp; MEDICINAL CHEMISTRY LETTERS, Vol. 7, No. 7, pp. 949-954, 1997

Examiner  
Signature

Date

Considered

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.